Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Ponatinib lung squamous cell carcinoma sensitive detail...
DDR2 S768R Dasatinib lung squamous cell carcinoma predicted - sensitive detail...
DDR2 L63V Dasatinib lung squamous cell carcinoma sensitive detail...
DDR2 L239R Dasatinib lung squamous cell carcinoma sensitive detail...
DDR2 I638F DDR2 T654M Dasatinib lung squamous cell carcinoma decreased response detail...
DDR2 I638F Dasatinib lung squamous cell carcinoma sensitive detail...
DDR2 I638F Ponatinib lung squamous cell carcinoma sensitive detail...
Unknown unknown Cisplatin + Gemcitabine + Necitumumab lung squamous cell carcinoma not applicable detail...
Unknown unknown Cisplatin + Necitumumab + Pemetrexed Disodium lung squamous cell carcinoma not applicable detail...
PDGFRA amp Dasatinib lung squamous cell carcinoma sensitive detail...
DDR2 mutant Dasatinib lung squamous cell carcinoma sensitive detail...
DDR2 L239R DDR2 T654M Dasatinib lung squamous cell carcinoma decreased response detail...
PDGFRA amp Imatinib lung squamous cell carcinoma sensitive detail...
DDR2 L239R Ponatinib lung squamous cell carcinoma sensitive detail...
DDR2 S768R Dasatinib + Erlotinib lung squamous cell carcinoma predicted - sensitive detail...
ERBB2 amp Gefitinib lung squamous cell carcinoma resistant detail...
FGFR1 amp Dovitinib lung squamous cell carcinoma no benefit detail...
PIK3CA over exp Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA H1047R Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA over exp Dactolisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K Dactolisib lung squamous cell carcinoma sensitive detail...
PIK3CA H1047R Dactolisib lung squamous cell carcinoma sensitive detail...
PIK3CA H1047R Alpelisib lung squamous cell carcinoma sensitive detail...
PIK3CA E545K Alpelisib lung squamous cell carcinoma sensitive detail...
PIK3CA over exp Alpelisib lung squamous cell carcinoma sensitive detail...
FGFR1 amp RO4987655 lung squamous cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung squamous cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung squamous cell carcinoma no benefit detail...
HRAS Q61L Selumetinib lung squamous cell carcinoma sensitive detail...
HRAS Q61L Buparlisib lung squamous cell carcinoma no benefit detail...
HRAS Q61L Everolimus + Selumetinib lung squamous cell carcinoma sensitive detail...
HRAS Q61L Binimetinib + Everolimus lung squamous cell carcinoma sensitive detail...
HRAS Q61L AZD8055 + Binimetinib lung squamous cell carcinoma sensitive detail...
FGFR1 amp Infigratinib lung squamous cell carcinoma sensitive detail...
Unknown unknown Docetaxel + Trametinib lung squamous cell carcinoma not applicable detail...
FGFR1 amp AZD4547 + Buparlisib lung squamous cell carcinoma sensitive detail...
FGFR3 positive Rogaratinib lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 amp AZD4547 lung squamous cell carcinoma no benefit detail...
ERBB2 mutant Afatinib lung squamous cell carcinoma predicted - sensitive detail...
ERBB4 mutant Afatinib lung squamous cell carcinoma predicted - sensitive detail...
Unknown unknown Prexasertib lung squamous cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Paclitaxel + Pembrolizumab lung squamous cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Nab-paclitaxel + Pembrolizumab lung squamous cell carcinoma not applicable detail...
PIK3CA amp Buparlisib lung squamous cell carcinoma no benefit detail...
PIK3CA act mut Buparlisib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA E545K PIK3CA amp Buparlisib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA E542K PIK3CA amp Buparlisib lung squamous cell carcinoma sensitive detail...
PIK3CA act mut Alpelisib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA E542K PIK3CA amp Alpelisib lung squamous cell carcinoma sensitive detail...
CDKN2A loss PIK3CA act mut Buparlisib + Palbociclib lung squamous cell carcinoma predicted - sensitive detail...
CDKN2A loss PIK3CA E545K PIK3CA amp Buparlisib + Palbociclib lung squamous cell carcinoma sensitive detail...
CDKN2A loss PIK3CA E542K PIK3CA amp Buparlisib + Palbociclib lung squamous cell carcinoma sensitive detail...
ERBB2 S310Y Afatinib lung squamous cell carcinoma predicted - sensitive detail...
FGFR1 amp Debio 1347 lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA mutant Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA E545K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA E542K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA H1047R Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA N345K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA E453K Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA G1049R Taselisib lung squamous cell carcinoma no benefit detail...
PIK3CA M1043I Taselisib lung squamous cell carcinoma no benefit detail...
DDR2 L239R DDR2 T654I Dasatinib lung squamous cell carcinoma predicted - resistant detail...
Unknown unknown CX-2029 lung squamous cell carcinoma not applicable detail...
CDKN2A loss Palbociclib lung squamous cell carcinoma predicted - sensitive detail...
PIK3CA mutant Capivasertib lung squamous cell carcinoma no benefit detail...
PIK3CA amp Capivasertib lung squamous cell carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting
NCT01741727 Phase II Depatuxizumab mafodotin A Study of ABT-414 in Subjects With Solid Tumors Completed
NCT01820325 Phase II Buparlisib Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Terminated
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed
NCT01948141 Phase II Nintedanib Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens Completed
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed
NCT02154490 Phase II Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02403895 Phase II Vistusertib Paclitaxel AZD2014 and Weekly Paclitaxel in Squamous NSCLC Terminated
NCT02417701 Phase II Sapanisertib Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer Recruiting
NCT02443337 Phase II Necitumumab LY3023414 A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Terminated
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02513563 Phase II Carboplatin + Paclitaxel Adavosertib AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Recruiting
NCT02536495 Phase Ib/II Docetaxel Selinexor Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Withdrawn
NCT02785913 Phase II Taselisib Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Completed
NCT02785939 Phase II Palbociclib Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting
NCT02785952 Phase III Nivolumab Ipilimumab + Nivolumab Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting
NCT02924233 Phase Ib/II Nivolumab + SYM004 Nivolumab Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer Withdrawn
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting
NCT03157089 Phase II Afatinib + Pembrolizumab Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO) Completed
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) Active, not recruiting
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Recruiting
NCT03261947 Phase II TAK-931 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Active, not recruiting
NCT03377556 Phase II Talazoparib Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting
NCT03574753 Phase II Telisotuzumab vedotin Lung-MAP S1400K: c-MET Positive Active, not recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting
NCT03976362 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Olaparib + Pembrolizumab A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) Recruiting
NCT03976375 Phase III Lenvatinib Lenvatinib + Pembrolizumab Docetaxel Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Recruiting
NCT04043195 Phase Ib/II Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) Recruiting
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Recruiting
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting
NCT04262856 Phase II AB154 + AB928 + GLS-010 GLS-010 AB154 + GLS-010 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) Recruiting
NCT04266730 Phase I PANDA-VAC + Pembrolizumab + Poly ICLC Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC) Not yet recruiting
NCT04350463 Phase II CC-90011 + Nivolumab A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers Recruiting
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Not yet recruiting